trending Market Intelligence /marketintelligence/en/news-insights/trending/mUI8R1DZwRRIUMlfSW8eRg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Axsome stock up 84% premarket as drug reduces depression in phase 3 trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Axsome stock up 84% premarket as drug reduces depression in phase 3 trial

Axsome Therapeutics Inc. said AXS-05 improved symptoms of depression in patients, meeting the main goal of a late-stage clinical trial.

The New York-based biopharmaceutical company's stock was up by 84.04% to $86.11 in pre-market trading on Dec. 16.

Axsome's phase 3 trial called Gemini enrolled 327 adult patients with confirmed moderate to severe major depressive disorder. Patients received either AXS-05 or a placebo.

Major depressive disorder is a mood disorder that causes persistent feelings of sadness and loss of interest, which can lead to emotional and physical problems for patients. About 17 million people in the U.S. experience the disorder each year, Axsome said in a Dec. 16 press release.

After six weeks of treatment, patients on AXS-05 showed a reduction in depression severity, compared to those taking placebo. The therapy also demonstrated statistically significant improvements in all secondary goals of the study. The company said the drug was well-tolerated, and the most commonly reported adverse events were dizziness, nausea and headache, among other things.

Axsome CEO Herriot Tabuteau said the company expects to file for a U.S. approval of AXS-05 in the second half of 2020 based on the results from Gemini and a previous trial called Ascend. In January, the company reported results from the phase 2 Ascend trial, which showed that the medicine helped reduce depression symptoms in patients.

AXS-05 received the U.S. Food and Drug Administration's fast-track designation for treatment-resistant depression and breakthrough-therapy status to treat major depressive disorder. The drug is also being evaluated in another phase 3 trial known as Stride-1 to treat patients with major depressive disorder who failed one or two prior antidepressant therapies.

In addition, AXS-05 has been shown to help reduce daily smoking in adults in a phase 2 trial. The company said AXS-05 is also being evaluated in patients with Alzheimer's disease agitation in a study called Advance-1.